Affimed Provides Clinical Response Update on AFM24-102 Trial in EGFR-wildtype Non-Small Cell Lung Cancer

January 19, 2024

https://www.globenewswire.com/news-release/2024/01/08/2805843/0/en/Affimed-Provides-Clinical-Response-Update-on-AFM24-102-Trial-in-EGFR-wildtype-Non-Small-Cell-Lung-Cancer.html

MANNHEIM, Germany, Jan. 08, 2024 (GLOBE NEWSWIRE) — Affimed N.V. (Nasdaq:AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today provided an update on the clinical response data for the ongoing AFM24-102 phase 1/2a study in EGFRwt NSCLC.

Read more at globenewswire.com

Related news for (AFMD)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.